medwireNews: The 1-year results from the DISCOVER-1 and DISCOVER-2 trials point to prolonged benefits of the interleukin-23 inhibitor guselkumab in patients with psoriatic arthritis (PsA).
Previously reported primary results from the two phase 3 trials showed that treatment with guselkumab 100 mg every 4 or 8 weeks significantly improved joint and skin symptoms over 24 weeks, and after this timepoint placebo-treated patients in both trials were switched to the higher dose of guselkumab.
As shown in a poster presentation at the EULAR 2020 E-Congress, 1-year ACR20 response rates in DISCOVER-1 were 73.4% for the 128 patients treated with the higher dose of guselkumab, 59.8% for the 127 given the lower dose, and 56.3% for the 126 who switched from placebo to guselkumab. Christopher Ritchlin (University of Rochester Medical Center, New York, USA) and co-investigators said that “response rates or mean improvements continued to rise through 1 year” for most study outcomes.
Similarly, in DISCOVER-2, the 1-year ACR20 response rates were 70.6%, 74.6%, and 64.2% for patients in the higher dose (n=245), lower dose (n=248), and placebo-switching (n=246) groups, respectively. Iain McInnes (University of Glasgow, UK) and colleagues reported that the majority of endpoints improved over the study period.
Both trials reported a favorable safety profile of guselkumab over 1 year that was consistent with the known safety profile in psoriasis.
DISCOVER-1 included patients who were either biologic-naïve or had previously been treated with up to two tumor necrosis factor inhibitors, while DISCOVER-2 involved only biologic-naïve patients and included structural damage endpoints.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group